KMO and psychiatric disorder: The conclusion of a systematic review on peripheral and central kynurenine metabolites in psychiatric disorders was that brain/CSF KYNA levels are increased, whereas metabolites of the KMO-driven branch of the kynurenine pathway (e.g., 3-HK, XA, and QUINA) are unchanged in schizophrenia47.